Bertrand Cariou

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

Bertrand Cariou, Samy Hadjadj, Matthieu Wargny et al. · Diabetologia · 2020 · 830 citations · Full text

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Evan A. Stein, Robert Dufour et al. · The Lancet · 2014 · 734 citations

Metabolic Syndrome, Lipid Disorder, Heterozygous Familial Hypercholesterolaemia +11

The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice

Bertrand Cariou, Kirsten van Harmelen, Daniel Durán-Sandoval et al. · Journal of Biological Chemistry · 2006 · 536 citations · Full text

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

J.‐F. Yale, George L. Bakris, Bertrand Cariou et al. · Diabetes Obesity and Metabolism · 2013 · 480 citations · Full text

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

Vanita R. Aroda, Stephen C. Bain, Bertrand Cariou et al. · The Lancet Diabetes & Endocrinology · 2017 · 414 citations

Sustain 4, Diabetes Management, Insulin-naive Patients +8